S

Sanofi

Global pharma company; vaccines and R&D

Quality Control Expert

Full-TimeUpdated on 10/15/2026Deadline 12/20/26
No salary listed
Senior
Bachelor's, Master's, PhD
Beijing, China
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A degree in Chemistry, Pharmacy, Biochemistry, or equivalent is required.
  • A master's or PhD-level qualification in science is ideal.
  • At least 5 years of experience in the pharmaceutical or biotechnological industry is required.
  • At least 2 years of experience in project leadership positions with a proven track record of delivery and compliance is required.
  • Experience with analytical method transfer or verification, and/or instrument qualification and validation, is preferred.
  • Knowledge and experience in process analytical technology, automation, and/or laboratory information management systems are preferred.
  • Experience in scientific and technical writing is required.
  • Familiarity with strategic planning, balanced judgment, and risk analysis is required.
  • Proficiency with typical analytical techniques and software is required.
  • An in-depth understanding of Good Manufacturing Practice principles and data integrity requirements is required.
  • Knowledge of Good Manufacturing Practice and health-regulated requirements is required.
  • International and U.S. Food and Drug Administration experience is required.
  • Proficiency in academic English, German, and Mandarin across listening, speaking, reading, and writing is required.
  • Ability to drive and embrace change is required.
  • Cross-functional collaboration, leadership and assertiveness, people development, negotiation and influencing, communication, and decision-making skills are required.
Responsibilities
  • Provide analytical expertise for projects, including troubleshooting and investigations related to analytical methods and laboratory technologies.
  • Create and review protocols and reports related to analytical validation, transfer activities, and qualification measures.
  • Create, review, and maintain standard operating procedures for analytical methods at IFB, ensuring alignment with the sending unit in Frankfurt.
  • Perform assigned tasks, initially focused especially on equipment qualifications and analytical transfers, in accordance with current Good Manufacturing Practice and health, safety, and environment requirements, instructions, procedures, and records.
  • Document all required raw data, calculations, and information to comply with Good Manufacturing Practice and data integrity requirements.
  • Timely inform the line manager about quality- or health, safety, and environment-relevant events, including deviations and out-of-quality events, to ensure appropriate investigation and impact assessment.
  • Document deviations, non-conformities, and corrective actions.
  • Ensure Good Manufacturing Practice-compliant execution and documentation of quality tests and workflows for pharmaceutical products.
  • Deliver the quality control laboratory aspects of the project within the allocated budget and schedule and in line with expected objectives, performance, health, safety, environment, and quality requirements, Sanofi standards, and good practices.
  • Lead a team of internal and/or external analysts and technicians, providing training, mentoring, coaching, review, and development to support retention and succession planning across key positions.
  • Implement statutory and company-specific occupational safety guidelines within the area of responsibility, including communicating safety topics and conducting occupational safety training based on risk assessments.
  • Standardize operational processes and manage costs with a focus on continuous improvement.
  • Collaborate closely with the sending unit in Frankfurt, Manufacturing Science and Technology, and the global subject matter expert network.
Desired Qualifications
  • Knowledge and experience in process analytical technology, automation, and/or laboratory information management systems.
  • Practical experience in analytical method transfer or verification, and/or instrument qualification and validation.
  • A master's or PhD-level qualification in science.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)